# Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

> **NCT05636267** · PHASE1,PHASE2 · TERMINATED · sponsor: **Akeso** · enrollment: 59 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** AK119
- **DRUG:** AK112
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05636267
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-10
- **Primary completion:** 2025-02-24
- **Final completion:** 2025-04-15
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Terminated due to sponsor strategic development reprioritization.
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05636267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05636267, "Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05636267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*